The recent advent of precision medicine for the treatment of PC is slowly changing the prognosis of the subgroup of patients affected by metastatic disease carrying somatic or germline pathogenic/likely pathogenic variants (P/LPVs) in BRCA1 or BRCA2. The gene discussed is BRCA1; the disease is pachyonychia congenita.